People's Health Press
ISSN 2096-2738 CN 11-9370/R
  • Official WeChat

  • Official Weibo

  • Official headlines

Electronic Journal of Emerging Infectious Diseases ›› 2020, Vol. 5 ›› Issue (3): 195-197.doi: 10.19871/j.cnki.xfcrbzz.2020.03.012

Previous Articles     Next Articles

Dolutegravir for rapid viral suppression in acute HIV infection

Meng Zhihao1, Qin Shanfang1, Liu Aimei1, Shen Yinzhong2   

  1. 1. Department of Infectious Disease, Longtan Hospital of Guangxi Autonomous Region, Guangxi Liuzhou 545005, China;
    2. Department of Infectious and Immunology Disease, Public Health Clinical Center, Shanghai 201508, China
  • Received:2019-09-18 Online:2020-03-20 Published:2020-10-12

Abstract: Objective To explore the early diagnosis and treatment for acute HIV infection. Methods A patient with acute HIV infection were analyzed in the aspect of clinical manifestations, treatment course and prognosis. Results One week after high-risk behavior, the patient developed fever, fatigue, headache, etc. 15 days later, this patient's HIV antibody screening test was positive, but confirmation test was uncertain. This patient's HIV-1 RNA was 8 847 000 copies/ml with CD4+T cell count of 173/mm3, indicating the diagnosis of acute HIV infection. TDF+3TC+DTG regimen was given as initial antiviral treatment. After 4 weeks, HIV-1 RNA was 3303 copies/ml and was dropped to 150copies/million cells after 3 months. After 6 months of antiviral treatment, CD4+T cell count was increased to 530/mm3 with viral load decreased to 75copies/ml. Conclusion RNA testing is helpful for the diagnosis of acute HIV-1 infection. Early initiation of antiviral therapy with Integrase Inhibitor during acute HIV infection stage can rapidly reduce the viral load, enhance CD4+T cells recovery and reduce the HIV-1 DNA load to an extremely low level.

Key words: Acute human immunodeficiency virus infection, Integrase Inhibitor, Dolutegravir